Ongoing commercial launch of AUCATZYL® on track, with 24 treatment centers fully authorized as of January 10th- National Comprehensive Cancer ...

The addition of Monjuvi to standard-of-care therapy reduced the risk of disease progression, relapse, or death in patients ...

Cabaletta Bio’s financials and CAR T-cell therapy show potential but face risks. Discover why CABA stock is a risky yet ...

CD19-CD22 CAR-T cells is under clinical development by Shanghai Biomed-Union Biotechnology and currently in Phase II for Unspecified B-Cell Lymphomas.

To begin, lymphocytes are a type of white blood cell that helps the body fight infection. There are two main types of lymphocytes: B-lymphocytes and T-lymphocytes. Of these, there are two types of ...

CD4 T helper cells are a type of white blood cell called a lymphocyte that serves an important role in your immune system. These cells help defend the body against infection by directing other "killer ...

Tumor-infiltrating lymphocytes (TILs ... and often restricted access to these therapies. Anti-CD19 CAR-T cells can expand rapidly in the recipient, causing significant increases in proinflammatory ...

Clinical improvement and a rapid decline in CD19 + B cell count were observed after the administration of OFA. This pioneering report demonstrates the potential utility of OFA in treating anti-Yo ...

别称： B-lymphocyte antigen CD19, Cluster of Differentiation 19, B-Lymphocyte Surface Antigen B4, T-Cell Surface Antigen Leu-12, CVID3 概述： 悉得（Syd Labs）提供重组小鼠 IgG1 ...

It is a two-component therapy consisting of SYNCAR-001, an autologous CD19-targeting chimeric antigen receptor T (CAR-T) cell which expresses an engineered IL-2 receptor, and STK-009, an ...